DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA reduced its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 41.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,430,964 shares of the medical device company’s stock after selling 1,008,069 shares during the period. Massachusetts Financial Services Co. MA owned about 0.37% of DexCom worth $95,932,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also modified their holdings of DXCM. Advisors Asset Management Inc. grew its position in DexCom by 13.9% in the 1st quarter. Advisors Asset Management Inc. now owns 14,800 shares of the medical device company’s stock valued at $2,053,000 after acquiring an additional 1,809 shares in the last quarter. Ascent Group LLC boosted its stake in shares of DexCom by 3.7% in the first quarter. Ascent Group LLC now owns 6,295 shares of the medical device company’s stock valued at $873,000 after purchasing an additional 222 shares during the period. Zurich Insurance Group Ltd FI grew its holdings in shares of DexCom by 106.5% in the first quarter. Zurich Insurance Group Ltd FI now owns 429,471 shares of the medical device company’s stock valued at $59,568,000 after purchasing an additional 221,525 shares in the last quarter. BlueCrest Capital Management Ltd purchased a new stake in DexCom during the 1st quarter worth approximately $1,248,000. Finally, Kennedy Capital Management LLC acquired a new stake in DexCom during the 1st quarter worth approximately $1,690,000. 97.75% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other DexCom news, COO Jacob Steven Leach sold 746 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the sale, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at $18,318,872.25. This represents a 0.28 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Sadie Stern sold 4,259 shares of the stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the sale, the executive vice president now directly owns 71,192 shares of the company’s stock, valued at $5,320,178.16. The trade was a 5.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 5,431 shares of company stock valued at $399,319 in the last ninety days. 0.30% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research firms have commented on DXCM. Barclays dropped their price target on shares of DexCom from $138.00 to $113.00 and set an “equal weight” rating for the company in a research note on Monday, July 29th. Sanford C. Bernstein upped their price target on DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a report on Friday, October 25th. StockNews.com lowered DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Royal Bank of Canada lowered their price objective on DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Finally, Raymond James reduced their target price on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a report on Friday, October 25th. Seven equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $104.59.

DexCom Trading Down 2.2 %

DXCM opened at $72.83 on Friday. The firm has a market cap of $28.45 billion, a price-to-earnings ratio of 43.61, a price-to-earnings-growth ratio of 2.28 and a beta of 1.17. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00. The business’s 50 day moving average is $70.61 and its two-hundred day moving average is $89.83. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.